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Danser. High-affinity prorenin binding to cardiac man-6-P/
IGF-II receptors precedes proteolytic activation to renin. Am
J Physiol Heart Circ Physiol 280: H1706–H1715, 2001.—
Mannose-6-phosphate (man-6-P)/insulin-like growth fac-
tor-II (man-6-P/IgF-II) receptors are involved in the activa-
tion of recombinant human prorenin by cardiomyocytes. To
investigate the kinetics of this process, the nature of activa-
tion, the existence of other prorenin receptors, and binding of
native prorenin, neonatal rat cardiomyocytes were incubated
with recombinant, renal, or amniotic fluid prorenin with or
without man-6-P. Intact and activated prorenin were mea-
sured in cell lysates with prosegment- and renin-specific
antibodies, respectively. The dissociation constant (Kd) and
maximum number of binding sites (Bmax) for prorenin bind-
ing to man-6-P/IGF-II receptors were 0.6 6 0.1 nM and
3,840 6 510 receptors/myocyte, respectively. The capacity for
prorenin internalization was greater than 10 times Bmax.
Levels of internalized intact prorenin decreased rapidly
(half-life 5 5 6 3 min) indicating proteolytic prosegment
removal. Prorenin subdivision into man-6-P-free and man-6-
P-containing fractions revealed that only the latter was
bound. Cells also bound and activated renal but not amniotic
fluid prorenin. We concluded that cardiomyocytes display
high-affinity binding of renal but not extrarenal prorenin
exclusively via man-6-P/IGF-II receptors. Binding precedes
internalization and proteolytic activation to renin thereby
supporting the concept of cardiac angiotensin formation by
renal prorenin.
local renin-angiotensin system; cardiomyocytes; fibroblasts;
heart; kidney
THE BENEFICIAL CARDIAC EFFECTS of angiotensin-convert-
ing enzyme (ACE) inhibitors in subjects with heart
failure are usually attributed to interference of these
drugs with ANG II generation at cardiac tissue sites.
Although initially it was thought that this generation
depends on the de novo synthesis of renin in the heart,
it is now well established that such synthesis does not
occur either under normal circumstances (13, 24, 34,
35, 40, 56) or under pathological conditions (14, 31, 50).
Therefore, the heart must sequester renin from the
circulation to synthesize ANG II locally. Renin may
diffuse into the interstitial space (18, 28) or bind to
renin receptors and/or renin-binding proteins (8, 46,
53). Because renin in blood is predominantly present in
the form of its inactive precursor prorenin (11), it is
also conceivable that the heart sequesters prorenin
instead of renin. This prorenin must then be activated
locally. In support of this concept we recently demon-
strated that endothelial cells and cardiac myocytes and
fibroblasts, which do not synthesize (pro)renin (1, 59),
are capable of binding recombinant human prorenin to
cell-surface mannose-6-phosphate (man-6-P)/insulin-
like growth factor-II (man-6-P/IGF-II) receptors (1, 58).
Binding precedes rapid internalization and appear-
ance of renin-specific enzymatic activity. Furthermore,
the receptors also bound and internalized recombinant
human renin. It is well established that recombinant
human prorenin produced in Chinese hamster ovary
(CHO) cells contains the man-6-P signal that is re-
quired to bind to man-6-P/IGF-II receptors (2, 25). This
is not a unique property because many other prohor-
mones [e.g., latent transforming growth factor-b (19),
procathepsin D (29), and proliferin (39)] also carry the
man-6-P recognition marker, and these prohormones
(like prorenin) are activated after binding and inter-
nalization via man-6-P/IGF-II receptors.
At present it is unlikely that the man-6-P/IGF-II
receptor is the only renin- and prorenin-binding recep-
tor, because excess man-6-P did not block prorenin
binding to microsomal membrane fractions prepared
from various rat tissues (53). In addition, it is not
known whether intracellular prorenin activation oc-
curs proteolytically or nonproteolytically. Proteolytic
activation involves the actual removal of the proseg-
ment by any of the known prorenin-renin convertases
[e.g., cathepsin B (45), kallikrein (37), and prohormone
convertases (51)]. Nonproteolytic activation implies
transient unfolding of the prosegment so that it no
longer folds over the enzymatic cleft, thereby allowing
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prorenin to cleave angiotensinogen. In vitro, acid pH or
cold storage favor the latter type of activation (21).
Moreover, a recent study in mice has shown that non-
proteolytically activated prorenin is capable of gener-
ating ANG I at tissue sites in vivo (43).
The aim of the present study was to investigate in
neonatal rat cardiomyocytes and fibroblasts 1) the ki-
netics of man-6-P/IGF-II receptor-dependent prorenin
binding [dissociation constant (Kd), maximum number
of binding sites (Bmax)] and activation; 2) the possibil-
ity of prorenin binding independent of the man-6-P/
IGF-II receptor; 3) the nature of the prorenin activa-
tion (proteolytic or nonproteolytic) and, in case of
proteolytic activation, the nature of the prorenin-acti-
vating enzyme; and 4) possible differences between
binding of recombinant human prorenin and binding of
native human prorenin from renal and extrarenal
sources.
METHODS
Cell culture. All experiments were performed according to
the regulations of the Animal Care Committee of Erasmus
University Rotterdam, Rotterdam, The Netherlands, and in
accordance with the “Guiding Principles in the Care and Use
of Laboratory Animals” as approved by the Council of the
American Physiological Society.
Primary cultures of rat neonatal cardiac cells were pre-
pared as previously described (57). Briefly, ventricles of
Wistar strain rat pups (age 1–3 days) were minced and cells
were dispersed by eight subsequent trypsinization steps.
Nonmyocytes were separated from myocytes by differential
preplating. Myocytes were seeded in noncoated 12-well
plates (Corning Costar Europe; Badhoevedorp, The Nether-
lands) yielding a confluent monolayer of spontaneously beat-
ing cells at 1.5 3 105 cells/cm2 after 24 h. The preplated cells
(fibroblast fraction) were passaged after 4 days to noncoated
12-well plates yielding a confluent monolayer of 0.75 3 105
cells/cm2 after 2 days. The cells were maintained for 72 h in
a humidified incubator at 37°C with 5% CO2 in air and 1.5 ml
of growth medium consisting of a 4:1 (vol/vol) ratio of DMEM
(GIBCO Life Technologies; Breda, The Netherlands) and
medium 199 (GIBCO) supplemented with 5% FCS (Roche
Diagnostics; Almere, The Netherlands), 5% horse serum
(Sigma-Aldrich; Zwijndrecht, The Netherlands), 100 U/ml of
penicillin (Roche), and 100 mg/ml of streptomycin (Roche).
The incubations with prorenin (see Incubation of cells with
prorenin at 4 or 37°C) were carried out under serum-free
conditions. Before the start of each experiment, cells were
washed with 1 ml of warm (37°C) PBS consisting of (in mM)
140 NaCl, 2.6 KCl, 1.4 KH2PO4, and 8.1 Na2HPO4 (pH 7.4).
The cells were then preincubated either at 4 or 37°C for 30
min with 0.4 ml of incubation medium consisting of a 4:1
(vol/vol) ratio of DMEM and medium 199 supplemented with
1% (wt/vol) BSA (Sigma-Aldrich).
Prorenin preparation. Recombinant human prorenin was a
kind gift of Dr. S. Mathews (Hoffmann-LaRoche; Basel, Swit-
zerland). It was secreted by CHO cells transfected with a
vector containing human prorenin cDNA. To remove traces of
renin, the prorenin was partially purified by Cibacron blue
Sepharose affinity chromatography (Amersham Pharmacia
Biotech; Roosendaal, The Netherlands). The intrinsic renin
activity of the prorenin preparation before proteolytic activa-
tion was ,2% of the activity after complete proteolytic acti-
vation when the prorenin preparation contained ;2 3 105
U/l (4 mM) renin.
Man-6-P receptor affinity chromatography. To separate
prorenin into fractions that do or do not contain the man-6-P
signal, recombinant human prorenin was applied to a 0.5-ml
bovine liver man-6-P/IGF-II receptor column (kindly pro-
vided by Dr. S. Kornfeld, St. Louis, MO). The column was
equilibrated with column buffer containing 50 mM imidazole
at pH 6.5, 150 mM NaCl, 5 mM Na-b-glycerophosphate, 0.1%
(wt/vol) BSA, 6 mM antipain, 8 mM leupeptin, 6 mM pepstatin
A, 7 mM chymostatin (all from Sigma-Aldrich), and 10 kal-
likrein inhibitory U/ml of aprotinin (Bayer; Mijdrecht, The
Netherlands) (26). All manipulations were performed at 4°C.
After the application of recombinant human prorenin (500
units in 0.1 ml of column buffer), the column was washed
with column buffer (“column runthrough”). Subsequently, 10
mM man-6-P was added to the column buffer and man-6-P-
containing prorenin was eluted. Prorenin was measured in
0.5-ml fractions. Fractions corresponding to column run-
through (i.e., man-6-P-free prorenin) and man-6-P-contain-
ing prorenin were separately pooled, concentrated, and ad-
justed to contain PBS (pH 7.4) by Centricon C-30 ultrafiltration
(Amicon Bioseparations; Bedford, MA).
Incubation of cells with prorenin at 4 or 37°C. After prein-
cubation at 4 or 37°C for 30 min under serum-free conditions
(see Cell culture), experiments were started by replacing the
incubation medium by 4 or 37°C incubation medium contain-
ing either recombinant human prorenin (final concentration
3–1,000 U/l), man-6-P-free recombinant human prorenin (10
U/l), or man-6-P-containing recombinant human prorenin (10
U/l). Incubations at 37°C were also performed with pools of
human plasma and human amniotic fluid diluted to a 1:3
ratio with incubation medium. Plasma was obtained from
subjects with renal artery stenosis (one man and two women,
age 41–66 yr). Amniotic fluid was obtained from three
women (age 19–38 yr) after natural delivery. All incubations
at 4 or 37°C lasted 4 h and were performed in both the
presence and absence of 10 mM man-6-P to determine man-
6-P/IGF-II receptor-specific prorenin binding (58). To inves-
tigate the intracellular presence of man-6-P/IGF-II receptors
in myocytes, incubations with recombinant human prorenin
(1,000 U/l) at 4°C were also performed after prior permeabi-
lization of the cells with PBS containing 0.2% saponin
(Merck; Amsterdam, The Netherlands) (52). Finally, to de-
termine what proteases are responsible for prorenin activa-
tion, incubations at 37°C were performed in the presence of
the following five protease inhibitors: 0.04 mM 4-(2-aminoeth-
yl)-benzenesulfonylfluoride hydrochloride (AEBSF, Calbiochem;
LaJolla, CA); 0.1 mM leupeptin; 0.14 mM L-trans-3-carboxyoxi-
ran-2-carbonyl-L-leucylagmatine (E64, Sigma-Aldrich); 1.0 mM
1,10-phenanthroline (Merck); or 0.1 mM pepstatin A.
At the end of the incubation period the culture medium
was removed. Each well was washed three times with 1 ml of
ice-cold PBS. Prorenin was not detectable in the last PBS
wash. Cells were then lysed in 0.2 ml of ice-cold PBS con-
taining 0.2% Triton X-100 (Merck), and the cell lysates were
quickly frozen on dry ice. Cell lysates were stored at 270°C
until assays for total and cell-activated prorenin were per-
formed.
To determine whether prorenin had been internalized, the
acid-wash method was used (58). At low pH surface-bound
prorenin dissociates from the cells; internalized prorenin,
however, is acid resistant. Briefly, after the cells had been
washed three times with ice-cold PBS, cells were incubated
at 4°C with 0.4 ml of an acid solution containing 50 mM
glycine and 150 mM NaCl at pH 3.0. After 10 min the acid
solution was removed, the cells were washed and lysed as
described above, and the cell lysates were stored at 270°C
until being assayed.
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Incubation of cells at 4°C followed by incubation at 37°C.
To study the kinetics of prorenin activation in more detail,
cells cultured in six-well plates (Corning Costar) were loaded
with 1 ml of recombinant human prorenin-containing incu-
bation medium (final concentration 100 U/l) for 2 h at 4°C.
After this period, free prorenin was removed by washing the
cells three times with 3 ml of ice-cold PBS. After the last
wash, 1 ml of fresh incubation medium without prorenin at
37°C was added, and the cells were incubated at 37°C. The
incubation was terminated after 15, 30, 60, 120, 180, or 240
min by removing the culture medium and subsequently
washing the cells three times with 3 ml of ice-cold PBS. The
cells were then lysed in 0.5 ml of ice-cold PBS containing
0.2% Triton X-100 as described above. Culture medium and
cell lysate were stored at 270°C until assays for total prore-
nin, cell-activated prorenin, and intact propeptide-containing
prorenin were performed.
Prorenin measurement. In the experiments with recombinant
human prorenin in myocytes, cell-activated prorenin and total
prorenin (i.e., cell-activated plus nonactivated prorenin) were
measured by immunoradiometric assay (IRMA). The proteo-
lytic activation of recombinant human prorenin by myocytes
was monitored with an IRMA specific for intact prorenin, i.e.,
prorenin in which the propeptide was still bound to the renin
part of the molecule. The IRMAs are not sensitive enough to
measure the low levels of cell-activated and total recombinant
human prorenin in fibroblasts. The prorenin measurements in
these cells were therefore performed by enzyme-kinetic assay.
The renin and prorenin measurements in the experiments with
human plasma and human amniotic fluid were also performed
by enzyme-kinetic assay.
Enzyme-kinetic assay. Cell-activated recombinant prore-
nin and native renin were measured by incubating a 100-ml
sample for 3 h with a saturating amount of sheep renin
substrate at 37°C and pH 7.4 in the presence of serine
protease and angiotensinase inhibitors (58). The generated
ANG I was quantified by RIA. Results were expressed as
microunits per 1,000,000 cells or microunits per milliliter
medium using plasmin-activated recombinant human prore-
nin as a reference. The lower limit of detection was 1 mU/106
cells or 1 mU/ml of medium. To measure total recombinant
prorenin and native prorenin, the samples were first incu-
bated for 48 h at 4°C with plasmin (0.5 caseinolytic U/ml,
obtained from Chromogenix; Mo¨lndal, Sweden). This prein-
cubation with plasmin causes complete proteolytic activation
of prorenin. The serine protease inhibitor aprotinin (final
concentration 100 kallikrein-inhibiting U/ml) was added to
the incubation medium of the ANG I-generating step to
inactivate plasmin.
Immunoradiometric assays. The monoclonal antibodies
(MAb) used in these assays were MAb R3–36–16 (Nichols
Institute; Wychen, The Netherlands), which reacts equally
well with activated and nonactivated prorenin (Kd 5 0.6 pM)
(30), MAb R1–20–5 (Nichols Institute), which recognizes the
active site of renin (Kd 5 250 nM) (60), and MAb F258–37-B1
(a kind gift of Dr. S. Mathews, Hoffmann-LaRoche), which is
directed against the COOH-terminal part (P20-P43) of the
propeptide (Fig. 1) and does not react (,0.1%) with renin
(F. H. M. Derkx, unpublished observation). MAbs R1–20–5
and F258–37-B1 do not react (,0.1%) with intact inactive
prorenin. However, they do react with prorenin after the
treatment of prorenin with the renin inhibitor remikiren (0.1
mM; a kind gift of Dr. W. Fischli, Hoffmann-LaRoche; Basel,
Switzerland) for 48 h at 4°C (16). The renin inhibitor enters
the enzymatic cleft in which the active site is located, thereby
inducing a slow conformational change of the inactive
(“closed”) form of the prorenin molecule into the active
(“open”) form. This nonproteolytic conformational change not
only allows subsequent recognition of the active site by MAb
R1–20–5, it also causes the propeptide to move to the surface
of the molecule so that it can react with MAb F258–37-B1. In
the IRMA for cell-activated and total prorenin, 200 ml of
untreated and remikiren-treated sample (diluted to a 1:9
ratio in heat-inactivated sheep serum, obtained from Bio-
trading; Mijdrecht, The Netherlands), respectively, were in-
cubated for 6 h at 37°C with biotinylated MAb R3–36–16,
125I-labeled R1–20–5 (250,000 counts/min), and an avidin-
coated bead as described (15). In the IRMA for intact propep-
tide-containing prorenin, 250 ml of remikiren-treated sample
(diluted to a 1:4 ratio in heat-inactivated sheep serum) were
incubated for 6 h at 37°C with an avidin-coated bead to which
1.6 mg of biotinylated MAb F258–37-B1 had been bound (1).
The bead was then washed three times with 2 ml of PBS
containing 0.1% (wt/vol) BSA and subsequently incubated
with 100 ml (250,000 counts/min) of 125I-labeled MAb R1–20–
5 and 200 ml of heat-inactivated sheep serum containing 0.1
mM remikiren for 24 h at room temperature. After the 6-h
and 24-h incubation periods, the beads in both IRMAs were
washed three times with 2 ml of PBS containing 0.01%
(vol/vol) Triton X-100, and bound radioactivity was measured
in a gamma-counter. The results of these assays were ex-
pressed as microunits per 1,000,000 cells using intact recom-
binant human prorenin as a reference. The lower limit of
detection was 5 mU/106 cells.
Statistical analysis. Results are expressed as means 6 SE.
Data were compared using Student’s t-test for paired obser-
vations or ANOVA. A value of P , 0.05 was considered to be
significant. Binding data were analyzed by nonlinear regres-
sion analysis using the GraphPad Prism (version 3) computer
program (GraphPad; San Diego, CA).
RESULTS
Incubation of myocytes and fibroblasts with recombi-
nant human prorenin at 4 or 37°C. Myocytes (Fig. 2)
and fibroblasts (Fig. 3) bound recombinant human pro-
Fig. 1. Prorenin isoforms and recognition sites of the
monoclonal antibodies used in the present study.
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renin in a concentration-dependent manner at both 4
and 37°C. Cell-associated prorenin at 37°C but not at
4°C was acid resistant (data not shown), indicating
that prorenin internalization occurred at 37°C only.
For a given prorenin concentration in the medium, the
level of cell-associated total prorenin after 4 h of incu-
bation was 10–15 times higher at 37°C than at 4°C.
Binding of recombinant human prorenin to man-6-
P/IGF-II receptors: Kd and Bmax. Man-6-P significantly
reduced recombinant human prorenin binding in both
myocytes (Fig. 2A) and fibroblasts (Fig. 3A). The reduc-
tion was much smaller in fibroblasts than in myocytes,
suggesting that fibroblasts may contain a second pro-
renin binding site that cannot be blocked by man-6-P.
However, because the levels of cell-associated prorenin
after 4 h of incubation in the presence of man-6-P were
similar in myocytes and fibroblasts, a more likely ex-
planation is that non-man-6-P/IGF-II receptor-medi-
ated prorenin binding represents nonspecific binding
and that the man-6-P-induced reduction in prorenin
binding is smaller in fibroblasts because these cells
contain less cell-surface man-6-P/IGF-II receptors. In-
deed, Scatchard analysis revealed that binding of pro-
renin to man-6-P/IGF-II receptors occurred with simi-
Fig. 2. A: levels of cell-associated total
prorenin after incubation of myocytes
with recombinant human prorenin at
4°C for 4 h in the absence (F) or pres-
ence (E) of 10 mM mannose-6-phos-
phate (man-6-P). Man-6-P/insulin-like
growth factor-II (IGF-II) receptor-spe-
cific binding () was taken as the dif-
ference between levels of cell-associ-
ated prorenin with and without man-
6-P. Data are means 6 SE; n 5 8.
Dissociation constant (Kd) and maxi-
mum number of binding sites (Bmax)
were calculated from a plot according
to Scatchard (inset; B/F represents the
ratio of bound to free prorenin). B: lev-
els of cell-associated total (F) and cell-
activated (h) prorenin after incubation
of myocytes with recombinant human
prorenin at 37°C for 4 h. Data are
means 6 SE; n 5 7.
Fig. 3. A: levels of cell-associated total
prorenin after incubation of fibroblasts
with recombinant human prorenin at
4°C for 4 h in the absence (F) or pres-
ence (E) of 10 mM man-6-P. Man-6-P/
IGF-II-receptor-specific binding () was
taken as the difference between levels of
cell-associated prorenin with and with-
out man-6-P. Data are means 6 SE; n 5
4. Kd and Bmax were calculated from a
plot according to Scatchard (inset). B:
levels of cell-associated total (F) and cell-
activated (h) prorenin after incubation of
fibroblasts with recombinant human
prorenin at 37°C for 4 h. Data are
means 6 SE; n 5 4.
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lar affinity in both myocytes (Kd 5 0.6 6 0.1 nM; n 5 8)
and fibroblasts (Kd 5 0.8 6 0.2 nM; n 5 4) and that
Bmax was 3,840 6 510 sites/myocyte and 650 6 150
sites/fibroblast. Prior permeabilization of myocytes
with saponin increased man-6-P/IGF-II receptor-de-
pendent prorenin binding 7.7 6 0.4-fold (n 5 4), indi-
cating that .85% of the man-6-P/IGF-II receptors is
located intracellularly. Recycling of these intracellular
receptors to the cell membrane most likely explains
why the levels of cell-associated prorenin at 37°C are
much higher than at 4°C.
Does prorenin binding occur independently of man-
6-P/IGF-II receptors? To investigate whether prorenin
binding occurs independently of man-6-P/IGF-II recep-
tors, recombinant human prorenin was separated into
man-6-P-free and man-6-P-containing fractions with
the help of a bovine man-6-P/IGF-II receptor-affinity
column (Fig. 4). The amount of recombinant human
prorenin (38 6 1%; n 5 3) that was not bound by this
column (which did not contain the man-6-P signal)
resembled the amount of prorenin (38 6 2%) that
eluted only after the addition of man-6-P to the elution
buffer (which did contain the man-6-P signal). The
remaining prorenin eluted shortly after the first
runthrough peak (before the addition of man-6-P) and
was not investigated further.
Incubation of myocytes and fibroblasts with man-6-
P-containing prorenin resulted in cellular prorenin lev-
els that were ’1.5–2.5 times higher than observed
after incubation with nonfractionated prorenin (Fig. 5).
Assuming that only man-6-P/IGF-II receptors are in-
volved in prorenin binding, this is exactly what one
would predict when exposing cardiac cells to a prorenin
solution in which either all or only ’40% of the prore-
nin molecules carry the man-6-P signal.
Incubation with man-6-P-free prorenin resulted in
cellular prorenin levels that were equal to or lower
than the levels observed after incubation with nonfrac-
tionated prorenin in the presence of man-6-P (Fig. 5).
Because the latter level was similar for myocytes and
fibroblasts (Figs. 2A and 3A), this level most likely
represents nonspecific prorenin binding. Thus our find-
ings do not provide evidence for prorenin binding to
receptors other than the man-6-P/IGF-II receptor.
Activation of recombinant human prorenin: effect of
protease inhibitors. Activation of recombinant human
prorenin was detectable at 37°C only (Figs. 2B and 3B).
Saturation of the activation process did not occur be-
cause the percentage of cell-associated prorenin that
was activated was similar at all concentrations of pro-
renin to which the cells were exposed [ranging from
88 6 15% at 3 U/l to 78 6 8% at 1,000 U/l in myocytes
(n 5 7) and from 83 6 9% at 3 U/l to 75 6 9% at 1,000
U/l in fibroblasts (n 5 4)]. The serine protease inhibitor
AEBSF partially blocked the activation of prorenin in
myocytes but had no effect in fibroblasts (Table 1).
None of the other protease inhibitors that were tested
Fig. 4. Bovine liver man-6-P/IGF-II receptor-affinity chromatogra-
phy of recombinant human prorenin. Representative example is
shown. After application of prorenin (500 units), the column was
washed with column buffer (see METHODS). Man-6-P-containing pro-
renin was eluted with 10 mM man-6-P in column buffer.
Fig. 5. Levels of cell-associated total prorenin after incubation of
myocytes (A) or fibroblasts (B) with nonfractionated recombinant
human prorenin (rhPR, 10 U/l; control), man-6-P-containing recom-
binant human prorenin (PRM6P, 10 U/l), or man-6-P-free recombi-
nant human prorenin (PRnon-M6P, 10 U/l) at 4 or 37°C for 4 h in the
absence (open bars) or presence (filled bars) of 10 mM man-6-P. Data
are means 6 SE (n 5 3) expressed as a percentage of the cellular
levels of control. *P , 0.05 vs. control at 4°C; #P , 0.05 vs. control at
37°C.
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blocked prorenin activation in either myocytes or fibro-
blasts. The cysteine protease inhibitor E64 and the
mixed serine-cysteine protease inhibitor leupeptin in-
creased the level of cell-associated total prorenin by
40–50% in myocytes and by 40–80% in fibroblasts,
thereby indicating that cysteine proteases contribute
to (pro)renin degradation in cardiac cells.
Proteolytic or nonproteolytic activation of prorenin in
myocytes. After 2 h of incubation at 4°C with 100 U/l
prorenin and repeated washing with ice-cold PBS, the
level of cell-associated total prorenin was 350 6 45
mU/106 cells (n 5 7). Acid wash confirmed that at that
time, all cell-associated prorenin was located on the
cell surface. Immediately after the temperature was
raised to 37°C, the level of cell-associated intact (i.e.,
prosegment-containing) prorenin started to decrease.
The decrease followed a biphasic pattern (Fig. 6). The
first phase [half-life (t½) 5 5 6 3 min] corresponds with
the release of cell-surface-bound intact prorenin into
the medium and did not differ from the first phase that
was observed for total prorenin (t1⁄2 5 4 6 1 min). This
phase is determined by the rapidity of the internaliza-
tion process. The second phase represents the proteo-
lytic removal of the prosegment from internalized pro-
renin (t1⁄2 5 21 6 4 min), because a rise in the cellular
levels of activated prorenin was simultaneously ob-
served. These levels reached a maximum after 60 min
and then started to decrease, with a t1⁄2 (67 6 8 min)
similar to that of the second phase of total prorenin
(t1⁄2 5 74 6 5 min). Release of activated prorenin into
the medium could not be demonstrated during the 6-h
observation period (data not shown). Taken together,
these findings suggest that prorenin, after its internal-
ization, is rapidly activated by proteolytic cleavage of
the prosegment and that activated prorenin is subse-
quently metabolized by degrading enzymes without
being released into the medium.
Incubation of myocytes with native human (pro)renin
at 37°C. To verify man-6-P/IGF-II receptor-dependent
binding, internalization, and activation of native human
prorenin of renal and nonrenal origin, myocytes were
incubated at 37°C during 4 h with human plasma or
human amniotic fluid (diluted to a 1:3 ratio with incuba-
tion medium) in the presence or absence of man-6-P.
Expressed as a percentage of the sum of renin and pro-
renin, plasma and amniotic fluid contained 79 6 10% and
94 6 3% prorenin, respectively (Fig. 7). Incubation with
plasma resulted in man-6-P/IGF-II receptor-mediated
(pro)renin uptake by myocytes. After incubation with
plasma, myocytes contained predominantly (.75%) re-
nin (Fig. 7). Because man-6-P/IGF-II receptors bind and
internalize man-6-P-containing renin and prorenin
equally well (58), this is not due to selective uptake of
plasma renin. The increased renin-to-prorenin ratio in
cell lysates therefore suggests that internalized plasma
prorenin, like internalized recombinant human prorenin,
is activated to renin by myocytes. The cellular (pro)renin
levels after incubation with amniotic fluid were close to
the detection limit and did not differ with or without
man-6-P (Fig. 7). Thus amniotic fluid does not contain
prorenin that carries the man-6-P signal.
Table 1. Effect of protease inhibitors on cellular levels of total (i.e., cell-activated and nonactivated) prorenin
and cell-activated prorenin after incubating myocytes and fibroblasts for 4 h at 37°C with 100 U/l
recombinant human prorenin
Protease Inhibitor
Type Protease
Inhibited
Myocytes Fibroblasts
n
Total prorenin,
% of Control
Activated prorenin,
% of Total prorenin n
Total prorenin,
% of Control
Activated prorenin,
% of Total prorenin
None 7 100618 7566 5 100624 7766
Pepstatin A Aspartic 4 109612 8763 4 115610 8767
Leupeptin Serine and cysteine 5 14365* 8568 4 179618† 8566
AEBSF Serine 5 118617 5264* 4 7366 71610
E64 Cysteine 5 136610 70611 3 136615 82612
1,10-Phenanthroline Metallo 5 111617 6969 4 72620 6466
Data are means 6 SE; n, no. of myocytes or fibroblasts. AEBSF, 4-(2-aminoethyl)-benzenesulfonylfluoride hydrochloride; E64, L-trans-3-
carboxyoxiran-2-carbonyl-L-leucylagmatine. *P , 0.05 vs. control; †P , 0.01 vs. control.
Fig. 6. Time course of internalization and proteolytic activation of
prorenin by myocytes. Cells were preincubated with recombinant
human prorenin (100 U/l) for 2 h at 4°C and were washed with
ice-cold PBS. Fresh culture medium free of prorenin was added and
the incubation was continued at 37°C. Data are means 6 SE (n 5 7)
expressed as a percentage of the cellular levels of prorenin at the
end of the 2-h preincubation period (t 5 0). Total prorenin (F),
cell-activated prorenin (h), and intact prosegment-containing prore-
nin ( n ) are shown.
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DISCUSSION
The data of the present study show that man-6-P-
containing prorenin binds with high affinity to man-6-
P/IGF-II receptors on neonatal rat myocytes and fibro-
blasts. Binding is followed by internalization and
subsequent proteolytic activation to renin, possibly by
a serine protease. Internalization is greatly enhanced
by receptor recycling. Obtained with recombinant hu-
man prorenin, these results could be fully reproduced
with native human prorenin of renal origin (i.e., pro-
renin in human plasma) but not with native human
prorenin of extrarenal origin (i.e., prorenin in human
amniotic fluid), suggesting that local angiotensin pro-
duction by nonrenin-producing cells such as myocytes
and fibroblasts (59) depends on renin of renal origin.
Evidence for prorenin binding to receptors other
than the man-6-P/IGF-II receptor was not obtained.
First, man-6-P significantly reduced prorenin binding
in myocytes and fibroblasts. Although the reduction
was more modest in fibroblasts, prorenin binding in the
presence of man-6-P (i.e., “nonspecific” prorenin bind-
ing) was similar in myocytes and fibroblasts and did
not differ from prorenin binding to human umbilical
vein endothelial cells in the presence of man-6-P (data
not shown). These findings may point to the existence
of a second unidentified prorenin receptor. However, in
view of the similarity of the non-man-6-P/IGF-II recep-
tor-mediated prorenin binding in cardiac and endothe-
lial cells, a more likely explanation is that binding in
the presence of man-6-P represents nonspecific bind-
ing. Second, when exposing cardiac cells to a recombi-
nant human prorenin fraction in which all molecules
contain the man-6-P signal (as opposed to only 40% of
the molecules in the nonfractionated recombinant hu-
man prorenin preparation), binding and internaliza-
tion increased 1.5- to 2.5-fold. This is within the range
expected when increasing the level of man-6-P-contain-
ing prorenin ’2.5-fold and also indicates that the true
Kd is ’2.5-fold lower than the values reported here.
The increases were somewhat smaller in fibroblasts,
which is most likely due to the fact that man-6-P/
IGF-II receptor-specific prorenin binding in these cells
was comparable to prorenin binding not mediated via
man-6-P/IGF-II receptors (i.e., nonspecific prorenin
binding). A low number of cell-surface man-6-P/IGF-II
receptors also explains why the decrease in prorenin
binding in the presence of excess man-6-P was more
modest in fibroblasts than in myocytes.
Binding of prorenin to man-6-P/IGF-II receptors oc-
curred with high affinity (Kd , 1 nM), which suggests
that prorenin occupies both man-6-P binding sites of
this receptor (22, 38). In both fibroblasts and myocytes,
the levels of cell-associated prorenin increased 10–15-
fold when the cells were incubated with prorenin at
37°C instead of 4°C. This can be explained on the basis
of the internalization and continuous recycling of man-
6-P/IGF-II receptors among the cell surface and intra-
cellular compartments (e.g., Golgi and endosomes) that
are known to occur at 37°C but not at 4°C (10). In
myocytes, .85% of the man-6-P/IGF-II receptors were
found to be located in the cells. Internalization of the
receptor-prorenin complex appeared to occur rapidly
with a half-life of ,5 min and was followed by activa-
tion of prorenin. The rapid decline in the levels of
prorenin still containing the carboxy terminal part of
its prosegment [as measured with monoclonal antibody
F258–37-B1 (Fig. 6)] confirms that prorenin activation
was a proteolytic process and that cleavage occurred in
the correct manner. The cells did not release proteo-
lytically activated prorenin (i.e., renin) into the me-
dium. Instead, renin was degraded intracellularly with
a half-life of ;1 h. This raises the possibility that the
man-6-P/IGF-II receptor is involved in (pro)renin clear-
ance. Alternatively and perhaps more likely in view of
the rapid activation process, cell-activated prorenin
may contribute to intracellular angiotensin generation
before its destruction. Several studies have provided
evidence for intracellular angiotensin generation (17,
32, 42), and ANG II is known to activate intracellular
AT1 receptors in the cytosol and nucleus (23, 27). In the
absence of local renin synthesis, such intracellular
angiotensin generation will depend on the uptake of
circulating renin or prorenin. Moreover, because in
previous studies we were unable to demonstrate angio-
tensinogen synthesis in neonatal rat cardiac myocytes
and fibroblasts (59), it seems that renin substrate also
has to be internalized to allow intracellular angioten-
sin generation in the neonatal heart. This may be
different in the adult heart or under pathological con-
ditions (40). In addition, age as well as pathological
conditions may affect the density of cardiac man-6-P/
Fig. 7. Levels of total prorenin in medium and cell lysate after
incubation of myocytes with recombinant human prorenin, human
plasma (diluted to 1:3 ratio in incubation medium), or human amni-
otic fluid (diluted to 1:3 ratio in incubation medium) at 37°C for 4 h
in the absence or presence of 10 mM man-6-P. Solid region repre-
sents activated prorenin (i.e., renin). Data are means 6 SE ( n 5 4).
*P , 0.05 vs. without man-6-P; #P , 0.05 vs. recombinant human
prorenin; †P , 0.01 vs. plasma.
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IGF-II receptors and/or give rise to the appearance of
alternative (pro)renin receptors or uptake mechanisms
(4, 8, 46, 48, 53).
At present it cannot be concluded what enzymes are
responsible for the intracellular prorenin activation.
With the exception of the serine protease inhibitor
AEBSF, none of the protease inhibitors used in this
study exerted an inhibitory effect on prorenin activa-
tion. This is not due to the inability of these blockers to
reach the proper intracellular compartment because
others have demonstrated efficacy in the same setup
(7, 44). Moreover, the mixed serine-cysteine protease
inhibitor leupeptin and the cysteine protease inhibitor
E64 increased the levels of cell-associated prorenin by
.40%, indicating that cysteine proteases contribute to
(pro)renin degradation and that exogenous inhibitors
apparently are capable of reaching the intracellular
sites where degradation occurs. Possible candidates for
the prorenin-activating enzyme are kallikrein (37),
prohormone convertases (51), and cathepsin B (45),
although the latter seems unlikely in view of the ab-
sence of an inhibitory effect of E64. These enzymes
have been demonstrated in the heart (6, 41, 49, 55).
Furthermore, Baba and colleagues (3) described a
serine protease (mol mass 26 kDa) capable of activat-
ing prorenin in rat adrenal explant cultures. The pH
optimum for prorenin activation by this enzyme was
6.5. The rapid activation of prorenin in the present
study, which is indicative for early endosomal (i.e., at
pH 6.5) removal of the prosegment, as well as the
inhibitory effects of AEBSF on prorenin activation in
myocytes, is in agreement with the existence of a sim-
ilar serine protease in the heart.
Finally, our results are not limited to recombinant
human prorenin but also apply to native human
plasma prorenin. Plasma prorenin is predominantly of
renal origin (11), although extrarenal prorenin sources
such as the eye (12), ovary (20), placenta (33), and
testis (54) are also known to contribute to circulating
levels of prorenin. When incubated at 37°C for 4 h with
plasma containing prorenin (and low levels of renin),
myocytes were found to contain predominantly renin.
It is unlikely that this is due to selective uptake of
plasma renin because man-6-P/IGF-II receptors do not
make a distinction between man-6-P-containing renin
and prorenin (58). Therefore, these findings suggest
that plasma prorenin, like recombinant prorenin, is
activated intracellularly to renin. In absolute terms,
the levels of cell-associated renin and prorenin after
incubation with plasma were two to three times lower
than after incubation with equal amounts of recombi-
nant prorenin (Fig. 7). This may have at least two
explanations. First, the percentage of plasma prorenin
carrying the man-6-P signal may be lower than the
percentage of recombinant human prorenin carrying
this signal. Second, the high (in the nanomolar range)
levels of soluble man-6-P/IGF-II receptors that have
been reported in plasma (9) may affect prorenin bind-
ing to cellular man-6-P/IGF-II receptors, especially be-
cause the density of the latter (expressed per million
cells) is in the femtomole range. Studies reporting on
the presence of high-molecular-weight forms of prore-
nin in plasma (5, 47) are in agreement with the con-
tention that plasma prorenin is in part bound to solu-
ble man-6-P/IGF-II receptors. Further experiments are
required to resolve this issue. Interestingly, prorenin
present in human amniotic fluid did not bind to myo-
cytes, which suggests that this prorenin does not con-
tain the man-6-P signal. Amniotic fluid prorenin is
derived primarily from the placental chorion laeve (33)
(i.e., is synthesized extrarenally), and its isoelectric
focusing pattern differs from that of plasma prorenin
(36). The levels of soluble man-6-P/IGF-II receptors in
amniotic fluid are ;100 times lower than in plasma (9).
Whether prorenin from other extrarenal sources also
lacks the man-6-P signal is currently unknown, but if
so, this would imply that only prorenin of renal origin
is meant to be taken up by the heart and thus that
cardiac angiotensin generation is regulated by the kid-
ney and not by other (pro)renin-producing tissues.
Consequently, the release of large amounts of prorenin
from extrarenal sources [e.g., during pregnancy (33)]
would not necessarily result in increased cardiac an-
giotensin generation.
In conclusion, our data support the concept of cardiac
angiotensin generation by renal (pro)renin. Prorenin is
sequestered from the circulation by cardiac cells
through binding to man-6-P/IGF-II receptors. Binding
occurs with high affinity and is limited to prorenin
containing the man-6-P signal. After binding, the pro-
renin-man-6-P/IGF-II receptor complex is internalized
and prorenin is activated to renin, possibly by a serine
protease in an early endosomal compartment. The re-
ceptor then returns to the cell surface to repeat the
binding and internalization process. Activated prore-
nin may participate in intracellular ANG I production
before its destruction by cysteine proteases in lyso-
somes.
This study was supported by The Netherlands Heart Foundation
Research Grant NHS96–019.
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